Evidence mapPaperPMID 42496599Full record

ArticleBioinformatics (Oxford, England)2026

Quantifying uncertainty of predictions from cancer progression models.

Yanren Linda Hu, Simon Pfahler, Andreas Lösch, Stefan Vocht, Stefan Hansch, Kevin Rupp, Niko Beerenwinkel, Tilo Wettig, Rudolf Schill, Rainer Spang

Abstract read
In one paragraph

Article in Bioinformatics (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yanren Linda HuDepartment for Statistical Bioinformatics, University of Regensburg, Regensburg 93053, Germany.ORCID 0009-0002-7263-3635
Simon PfahlerDepartment of Physics, University of Regensburg, Regensburg 93040, Germany.ORCID 0009-0001-7364-4005
Andreas LöschDepartment for Statistical Bioinformatics, University of Regensburg, Regensburg 93053, Germany.ORCID 0009-0000-9100-2367
Stefan VochtDepartment for Statistical Bioinformatics, University of Regensburg, Regensburg 93053, Germany.ORCID 0009-0007-9077-1376
Stefan HanschDepartment for Statistical Bioinformatics, University of Regensburg, Regensburg 93053, Germany.ORCID 0000-0002-8458-4829
Kevin RuppDepartment of Biosystems Science and Engineering, ETH Zürich, Basel 4056, Switzerland.ORCID 0000-0002-4639-4717
Niko BeerenwinkelDepartment of Biosystems Science and Engineering, ETH Zürich, Basel 4056, Switzerland.ORCID 0000-0002-0573-6119
Tilo WettigDepartment of Physics, University of Regensburg, Regensburg 93040, Germany.ORCID 0000-0001-6732-9204
Rudolf SchillDepartment of Biosystems Science and Engineering, ETH Zürich, Basel 4056, Switzerland.ORCID 0000-0003-4649-7190
Rainer SpangDepartment for Statistical Bioinformatics, University of Regensburg, Regensburg 93053, Germany.ORCID 0000-0002-1326-4297

Funding

Free State of Bavaria [Marianne-Plehn-ProgramGerman Research FoundationSwiss Cancer League KFS-2977-08-2012Swiss National Science Foundation 179518
6 · The paper itself

Abstract

motivationCancer progresses through the accumulation of genomic events. Cancer progression models such as Mutual Hazard Networks (MHNs) describe this dynamic, enabling prediction of temporal event positions and patient-specific risks of acquiring mutations. However, current MHN analyses rely on single most likely models and do not quantify the uncertainty inherent to parameter estimation. Assessing forecast stability is essential before using them to anticipate treatment-relevant mutations, adapt targeted therapies, or prioritize monitoring of patients at elevated progression risk.

resultsWe address a key prerequisite for the responsible clinical use of cancer progression models by making MHN-derived predictions uncertainty-aware. We present a Bayesian framework for MHN that uses Markov Chain Monte Carlo to sample from the posterior distributions of model parameters and derived predictions. For practical use we implemented the Random-Walk Metropolis, Metropolis-Adjusted Langevin Algorithm (MALA), and simplified manifold MALA samplers as part of the existing mhn Python package. Only MALA and smMALA were successful in sampling from MHN posteriors, with MALA performing best. While most MHN parameters and predictions showed low posterior variance, a small subset displayed greater variability across the posterior distribution. This differentiation cannot be obtained from a single most likely model, emphasizing the need for uncertainty quantification, especially in clinical contexts. As an illustrative example, posterior sampling identified a subgroup of STK11$-$, KRAS$+$ lung adenocarcinoma patients with a high predicted short-term risk-with low variance across posterior samples-to develop an STK11 mutation. This subgroup exhibited poorer survival under immunotherapy, resembling patterns observed in STK11+ patients. AVAILABILITY AND IMPLEMENTATION: Our implementation is part of version 1.2.0 of the mhn package (https://github.com/spang-lab/LearnMHN). All analyses including the code to produce all figures in this article can be found under https://github.com/huy29433/MCMC-sampling-for-MHN (https://doi.org/10.5281/zenodo.21160219).

Indexed as

Computational BiologyNeoplasmsAlgorithmsBayes TheoremDisease ProgressionHumansMarkov ChainsMutationPrediction AlgorithmsUncertainty

Identifiers

PMID42496599
PMCPMC13437017

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.